Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2019 Update
December 2019
39
About the Report
About the Report
Summary
Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company's products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular's hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Ocular Therapeutix Inc, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
Acucela Inc
Otonomy Inc
Pfizer Inc
Neurocrine Biosciences Inc
Sorrento Therapeutics Inc
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Ocular Therapeutix Inc Company Overview
Ocular Therapeutix Inc Company Snapshot
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
Ocular Therapeutix Inc-Pipeline Analysis Overview
Ocular Therapeutix Inc-Key Facts
Ocular Therapeutix Inc-Major Products and Services
Ocular Therapeutix Inc Pipeline Products by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc Pipeline Products Overview
DEXTENZA
DEXTENZA Product Overview
DEXTENZA Clinical Trial
OTX-IVT
OTX-IVT Product Overview
OTX-MP
OTX-MP Product Overview
OTX-TIC
OTX-TIC Product Overview
OTX-TIC Clinical Trial
OTX-TKI
OTX-TKI Product Overview
OTX-TKI Clinical Trial
OTX-TP
OTX-TP Product Overview
OTX-TP Clinical Trial
Ocular Therapeutix Inc-Key Competitors
Ocular Therapeutix Inc-Key Employees
Ocular Therapeutix Inc-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Ocular Therapeutix Inc, Recent Developments
Nov 12, 2019: Ocular Therapeutix reports third quarter 2019 financial results and business update
Nov 08, 2019: Ocular Therapeutix announces strategic update and operational restructuring
Oct 01, 2019: Ocular Therapeutix announces permanent J-code for DEXTENZA (dexamethasone ophthalmic insert) effective October 1, 2019
Aug 07, 2019: Ocular Therapeutix reports second quarter 2019 financial results and business update
Jul 26, 2019: Ocular Therapeutix announces early assignment of permanent and specific J-Code (J1096) for DEXTENZA (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
Jul 11, 2019: Ocular Therapeutix announces Christopher White as Senior Vice President, Head of Business and Corporate Development
Jul 09, 2019: Ocular Therapeutix announces Patricia Kitchen as Chief Operations Officer
Jun 21, 2019: Ocular Therapeutix announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the treatment of Ocular Inflammation following Ophthalmic Surgery
May 10, 2019: Ocular Therapeutix reports first quarter 2019 financial results and business update
May 01, 2019: Ocular Therapeutix announces DEXTENZA (dexamethasone ophthalmic insert) recommended for unique J-code by CMS
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Ocular Therapeutix Inc Pipeline Products by Equipment Type
Ocular Therapeutix Inc Pipeline Products by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
List of Table
List of Tables
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
Ocular Therapeutix Inc Pipeline Products by Equipment Type
Ocular Therapeutix Inc Pipeline Products by Indication
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc, Key Facts
Ocular Therapeutix Inc, Major Products and Services
Ocular Therapeutix Inc Number of Pipeline Products by Development Stage
Ocular Therapeutix Inc Pipeline Products Summary by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc Ongoing Clinical Trials Summary
DEXTENZA-Product Status
DEXTENZA-Product Description
DEXTENZA-CLN-0052, A Multi-center, Randomized, Double-masked, Vehicle Controlled Phase III Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC)
DEXTENZA-Prospective Study on DEXTENZA Safety and Efficacy Following Concomitant MIGS and Cataract Surgery
OTX-IVT-Product Status
OTX-IVT-Product Description
OTX-MP-Product Status
OTX-MP-Product Description
OTX-TIC-Product Status
OTX-TIC-Product Description
OTX-TIC-To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension
OTX-TKI-Product Status
OTX-TKI-Product Description
OTX-TKI-A Phase 1 Open-label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects with Neovascular Age-related Macular Degeneration (AMD)
OTX-TP-Product Status
OTX-TP-Product Description
OTX-TP-A Prospective, Multicenter, Open Label Extension Study to Evaluate the Long Term Safety of OTX-TP
OTX-TP-Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug
Ocular Therapeutix Inc, Key Employees
Ocular Therapeutix Inc, Other Locations
Glossary
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.